RT Journal Article
SR Electronic
T1 Raloxifene and Bazedoxifene Could Be Promising Candidates for Preventing the COVID-19 Related Cytokine Storm, ARDS and Mortality
JF In Vivo
JO In Vivo
FD International Institute of Anticancer Research
SP 3027
OP 3028
DO 10.21873/invivo.12135
VO 34
IS 5
A1 KAREL SMETANA, JR.
A1 DANIEL ROSEL
A1 JAN BRÁBEK
YR 2020
UL http://iv.iiarjournals.org/content/34/5/3027.abstract
AB The FDA-approved drugs raloxifene and bazedoxifene could be among the best candidates to prevent mortality in severe COVID-19 patients. Raloxifene and bazedoxifene inhibit IL-6 signaling at therapeutic doses, suggesting they have the potential to prevent the cytokine storm, ARDS and mortality in severe COVID-19 patients, as is being shown with humanized antibodies blocking IL-6 signaling. In addition, raloxifene and bazedoxifene are selective estrogen receptor modulators with strong antiviral activity.